What is ELAPRASE ® (Idursulfase)? ELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 yrs and older.

ELAPRASE is administered as an intravenous infusion at a recommended dose of 0.5 mg per kg of body weight given once a week. 1. The recommended dose of ELAPRASE is dependent on the body weight of the Hunter syndrome patient. It is therefore important to weigh patients before each infusion to ensure correct dosing.

2025年1月1日 · Elaprase is an IV infusion used to treat some of the symptoms of a genetic condition called Hunter's syndrome, also called mucopolysaccharidosis (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis). Idursulfase contains a natural enzyme that some people lack because of a genetic disorder. Elaprase helps replace this missing enzyme.

ELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve...

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). [2] It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line. It is one of the most expensive drugs ever produced, costing US$567,412 per patient ...

ELAPRASE ® (idursulfase) is a prescription medicine for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II), which was approved by the Food and Drug Administration (FDA) in 2006. The active substance in ELAPRASE is an enzyme that breaks down glycosaminoglycans (GAG).

Elaprase（艾杜硫酶）是重组DNA来源的溶酶体酶人艾杜糖醛酸-2-硫酸酯酶的纯化形式。 它被设计用于替代天然酶，增加某些累积的糖胺聚糖（GAG）的分解代谢，其在粘多糖贮积症II（MPS-II或Hunter综合征）患者的多种组织类型中异常积累。 Elaprase特别适用于治疗成人和5岁及以上儿童的亨特综合征。 该药物已被证明可以改善这些受试者的行走能力。 Elaprase以无菌，水性澄清至微乳白色无色溶液形式提供，用于静脉输注。 推荐的初始剂量是每周输注0.5mg/kg。 初始 …

2025年3月9日 · ELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.

ELAPRASE is a formulation of idursulfase, a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell

Elaprase is used to treat patients with Hunter syndrome. It is designed for long-term use. Hunter syndrome, which is also known as mucopolysaccharidosis II, is a rare, inherited disease that primarily affects male patients.